1
Home
Companies

Remegen

Remegen
Leadership team

Dr. Jianmin Fang (Co-Founder, CEO, Chief Scientific Officer, Member of Scientific Advisory Board & Exec. Director)

Dr. Daotian Fu (Pres)

Mr. Jason Li (CFO & Joint Company Sec.)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
1,000 - 20,000
Headquarters
Yantai, Liaoning, China
Established
2008
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
SSE:688331
URL
https://www.remegen.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
History

Remegen was founded in 2015, driven by the advances in DNA manipulation and the promises of novel recombinant proteins for the development of novel diagnostics and therapies.

Mission
To develop and deliver novel diagnostics and therapies through recombinant proteins, with a focus on the development of autoimmune diagnostics and therapies.
Vision
We at Remegen strive to be a leader in protein recombinant technology, delivering innovative and economically viable medical solutions.
Key Team

Dr. Marie Zhu (Chief Technical Officer)

Dr. Ruyi He M.D. (Chief Medical Officer, Head of Clinical Research, Member of Scientific Adv. Board & Exec. Dir.)

Mr. Jian Lin (Exec. Director)

Mr. Kaisheng Huang (Chief Quality Officer)

Ms. Pak Yu Tam A.C.I.S., A.C.S. (Joint Company Sec.)

Mr. Qingkai Wen (Board Sec.)

Recognition and Awards
2015 MIT Technology Review TR35 Winner, 2016 Australia Bioinformatics Award, 2018 Best Biotech Startup Award
References

https://in.investing.com/equities/remegen-co-ltd

https://finance.yahoo.com/quote/9995.HK/profile?p=9995.HK

https://www.crunchbase.com/organization/remegen

https://www.remegen.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Remegen
Leadership team

Dr. Jianmin Fang (Co-Founder, CEO, Chief Scientific Officer, Member of Scientific Advisory Board & Exec. Director)

Dr. Daotian Fu (Pres)

Mr. Jason Li (CFO & Joint Company Sec.)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
1,000 - 20,000
Headquarters
Yantai, Liaoning, China
Established
2008
Net Income
20M - 100M
Revenue
100M - 500M
Traded as
SSE:688331
URL
https://www.remegen.com